// App-Quantinova.ai

2720 : Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

Researchers

Presenter

  • Pvel E Olivera

Principal Investigators

  • Desiree Campoy

  • Csar A Velasquez

  • Katia Flores

  • Tania Canals

  • Erik A Johansson

  • Laia Martinez

  • Jorge Sierra

  • Juan Jose Cerezo

  • Ramn Salinas

Medical Centers

  • Banc de Sang i Teixits, Unit of antithrombotic therapy, Barcelona, Spain

  • Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain

  • Department of Hematology, University Hospital Sagrat Cor, Barcelona, Spain

  • Department of Hematology, Fundación Sanitària Mollet, Barcelona, Spain

  • . Department of Hematology, General University Hospital of Catalonia, Barcelona, Barcelona, Catalonia, Spain

  • . Department of Hematology, University Hospital Sant Joan de Reus, Tarragona, Tarragona, Catalonia, Spain

  • Hospital de la Santa Creu i Sant Pau, IIB Sant Pau and Jose Carreras Leukemia Research Institute,Autonomous University of Barcelona,Barcelona,Spain

  • Department of Hematology, University Hospital Clínico Santa Lucía, Cartagena, Spain

  • Banc de Sang i Teixits, Head of Clinical Hematology, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Arrhythmia

  • Coronavirus disease

Biomarkers

  • Cytochrome P450 Family 3 Subfamily A Member 4

  • D-dimer

Drug/Treatment

  • Kaletra capsule

  • Hydroxychloroquine

  • Azithromycin

  • lopinavir

  • Ritonavir

  • Edoxaban

  • Heparin

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved